The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s showing significant efficacy in clinical trials for addressing obesity. Unlike some current weight loss approaches, retatrutide appears to provide a significant substantial